Drugs / Iodine-124
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00725946 | Feb 2008 → Dec 2012 | breast cancer | Stanford University | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06961084 | Dec 2025 → Apr 2028 expected | thyroid cancer | Thomas Hope | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-02 | Attralus, Inc. | Results Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology attralus.com ↗
AT-01 demonstrated to be highly accurate, with 100% sensitivity for detection of cardiac amyloid, across three independent investigator-initiated studies. |
| 2018-03-06 | Cellectar Biosciences, Inc. | Results Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology cellectar.com ↗
These Phase 1 data suggest that CLR124 is able to cross the blood-brain barrier and enter brain tumor cells, an important property for both diagnostic and therapeutic compounds. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iodine-124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961084 ↗ |
| Modality | Diagnostic / imaging agent | “Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET” NCT06961084 ↗ |
| Route | Oral | “Given Orally” NCT06961084 ↗ |